Evaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Sever… (NCT07583342) | Clinical Trial Compass
By InvitationPhase 4
Evaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute Pancreatitis
United States15 participantsStarted 2025-12-08
Plain-language summary
The goal of this study is to learn if Relizorb, a fat-digesting enzyme, can improve tolerance of tube feeds in adult patients with moderate to severe pancreatitis. The main question it aims to answer is:
Does Relizorb allow more nutrition to be delivered to participants than they received without it?
Participants will be observed with standard, universal monitoring after adding Relizorb to their nutrition regimen.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male or female aged 18 + years of age
* Admission to the Surgical Intensive Care Unit in the Northwell Health hospital system
* Moderate to severe acute pancreatitis based on Atlanta criteria
* Inability to tolerate ≥75% of goal EN (25 kcal/kg/d)
Exclusion Criteria:
* Moribund patients expected to expire within 120 hours
* Evidence of unresolved intestinal obstruction, ischemia, bleeding, perforation, fistulas or tract discontinuity, or other contraindication for enteral nutrition
* Diagnosis or evidence of C. Difficile or other gastrointestinal infection that may manifest with diarrhea
* Pre-existing constipation defined as laxative or stool softener use prior to admission to the hospital
* Patients receiving cancer-related treatment in the last 3 months
* History of cystic fibrosis
* Any other reason that the treating or investigator team considers to be a contraindication to enteral nutrition
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Percent of goal nutrition delivered at 72 hours
Timeframe: From enrollment to the end of treatment at 72 hours